External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.
- DOI
- 10.1002/cncr.70615
- Published
- 2026 Oct 1
- Container
- Cancer
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cncr.70615,
title = {External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.},
author = {Roy S and Armstrong AJ and Agarwal N and McKay RR and Jia AY and Lichtman-Mikol S and Barata PC and Garcia JA and Brown JR and Mumgandi Y and Basourakos SP and Sheng IY and Kishan AU and Zaorsky NG and Shoag JE and Morgan SC and Wallis CJD and Sun Y and Small EJ and Saad F and Shore ND and Spratt DE},
year = {2026},
journal = {Cancer},
doi = {10.1002/cncr.70615},
url = {https://doi.org/10.1002/cncr.70615}
}RIS
TY - JOUR TI - External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial. AU - Roy S AU - Armstrong AJ AU - Agarwal N AU - McKay RR AU - Jia AY AU - Lichtman-Mikol S AU - Barata PC AU - Garcia JA AU - Brown JR AU - Mumgandi Y AU - Basourakos SP AU - Sheng IY AU - Kishan AU AU - Zaorsky NG AU - Shoag JE AU - Morgan SC AU - Wallis CJD AU - Sun Y AU - Small EJ AU - Saad F AU - Shore ND AU - Spratt DE PY - 2026 JO - Cancer DO - 10.1002/cncr.70615 UR - https://doi.org/10.1002/cncr.70615 ER -
APA
S, R., AJ, A., N, A., RR, M., AY, J., S, L., PC, B., JA, G., JR, B., Y, M., SP, B., IY, S., AU, K., NG, Z., JE, S., SC, M., CJD, W., Y, S., EJ, S., F, S., ND, S., & DE, S. (2026). External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.. Cancer. https://doi.org/10.1002/cncr.70615
Source records
- pubmed · retrieved 2026-09-26T14:45:55.857Z